key: cord-0711093-z5j4i8h9
authors: Garrido, Isabel; Lopes, Susana; Macedo, Guilherme
title: Safety of COVID-19 Vaccination in Inflammatory Bowel Disease Patients on Biologic Therapy
date: 2021-10-30
journal: J Crohns Colitis
DOI: 10.1093/ecco-jcc/jjab189
sha: b8e219cc051e63e05ba67163cf8fdeca2c947f05
doc_id: 711093
cord_uid: z5j4i8h9

nan

The authors highlight that IBD patients should receive vaccination against SARS-CoV-2. In fact, the International Organization for the Study of IBD has already recommended vaccinating all patients with IBD as soon as they are able to receive the vaccine, regardless of immune-modifying therapies or disease activity. 2 Nevertheless, some articles have shown that a large percentage of IBD patients are unwilling to receive the COVID-19 vaccine due to fear of potential adverse events [AEs]. 3, 4 Moreover, individuals with IBD were excluded from safety and efficacy phase III vaccine trials, as well as those being treated with immunosuppressive therapies.

Thus, we performed a monocentric real-life survey to assess AEs of COVID-19 vaccination among IBD patients. All adult individuals with IBD undergoing biological treatment and followed at Centro 

Among vaccinated patients, the overall AE frequency was 56.8% after dose 1 [D1] and 74.1% after dose 2 [D2]. The two most common symptoms were localized injection-site reactions and fatigue. The vast majority of AEs were mild and lasted only a few days. Only four [1.7%] patients had IBD exacerbation after the vaccine. No serious AEs were reported and no patient was hospitalized. The percentage of AEs was higher among patients younger than 50 years [77.6% vs 62.5% after D1, p = 0.011; 83.0% vs 58.8% after D2, p = 0.002]. No significant differences were seen based on sex, vaccine type, biologic drug or disease type. Compared to the general population, a lower percentage of IBD patients suffered from local or systemic reactions during the first week after vaccination [ Figure 1 ]. 5 In conclusion, we found a high acceptance rate and a good safety profile of SARS-CoV-2 vaccination in IBD patients treated with biologics. Indeed, AEs were common but overall mild and transitory. These data support the prioritization and rapid vaccination of these individuals.

None.

SARS-CoV-2 vaccination in IBD: past lessons, current evidence, and future challenges

International Organization for the Study of Inflammatory Bowel Disease (IOIBD); International Organization for the Study of Inflammatory Bowel Diseases (IOIBD)

SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting

Inflammatory bowel disease and COVID-19 vaccination: a patients' survey

A global survey of potential acceptance of a COVID-19 vaccine

First month of COVID-19 vaccine safety monitoring -United States

The authors have no disclosures to report.

I.G. performed the literature review and drafted the manuscript. I.G., S.L. and G.M. critically revised and finalized the manuscript. All authors approved the final version of the manuscript. The data underlying this article are available in the article and in its online supplementary material. Guarantor of the article: I.G.